Related references
Note: Only part of the references are listed.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
TNFR2: Role in Cancer Immunology and Immunotherapy
Yang Yang et al.
IMMUNOTARGETS AND THERAPY (2021)
Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase
Olivier Vollmer et al.
AUTOIMMUNITY REVIEWS (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single-cell genomic approaches for developing the next generation of immunotherapies
Ido Yofe et al.
NATURE MEDICINE (2020)
CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes
Mirjana Efremova et al.
NATURE PROTOCOLS (2020)
Dendritic Cells and Their Role in Immunotherapy
Alycia Gardner et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Extended Polydimensional Immunome Characterization (EPIC) web-based reference and discovery tool for cytometry data
Joo Guan Yeo et al.
NATURE BIOTECHNOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors
Miro Viitala et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages
Harald Wajant et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Role of CXCR3 signaling in response to anti-PD-1 therapy
Xiao Han et al.
EBIOMEDICINE (2019)
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Lichun Ma et al.
CANCER CELL (2019)
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
David Tai et al.
CANCERS (2019)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
Nataly Manjarrez-Orduno et al.
FRONTIERS IN IMMUNOLOGY (2018)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance
Donnele Daley et al.
NATURE MEDICINE (2017)
Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
Valerie Chew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Human Tumor-infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Louise A. Elliott et al.
FRONTIERS IN IMMUNOLOGY (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis
J. Brasseit et al.
MUCOSAL IMMUNOLOGY (2016)
Membrane IL1α Inhibits the Development of Hepatocellular Carcinoma via Promoting T- and NK-cell Activation
Dandan Lin et al.
CANCER RESEARCH (2016)
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K. Subudhi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
Fan Yan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Kruppel-like factor 4 regulates macrophage polarization
Xudong Liao et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development
M. J. Wolf et al.
ONCOGENE (2010)
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells
Clare A. Notley et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)